Longmei Li1†
Yatong Chen1†
Shushu Wang2
Wanying Du3Tianfeng Lao1
Feng Chen4Gengzhen Yao1
Wensheng Chen1Xuewen Li1
Chunping Liu1Xiaoguang Xue1*- 1State Key Laboratory of Traditional Chinese Medicine Syndrome, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
- 2Chinese Medicine Guangdong Laboratory, Guangzhou University of Chinese Medicine, Zhuhai, Guangdong, China
- 3College of Basic Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
- 4School of Biology and Food Engineering, Changshu Institute of Technology, Changshu, Jiangsu, China
Diabetes Mellitus (DM) and Pancreatic Cancer (PC) are two major diseases that pose severe threats to global health, and their comorbidities have drawn increasing attention in recent years. Substantial epidemiological evidence indicates that type 2 diabetes mellitus (T2DM) is not only a risk factor for PC development but also an early clinical manifestation. The pathogenesis of these two conditions is interactive, wherein autophagy—a highly conserved intracellular catabolic process—plays a central role in maintaining pancreatic β-cell function, regulating insulin sensitivity, and determining the fate of PC cells. In diabetes, dysregulated autophagy contributes to β-cell failure and insulin resistance; in PC, autophagy plays a dual role, potentially suppressing tumorigenesis in early stages while supporting cancer cell survival and proliferation during progression, thereby mediating chemotherapy resistance. We review the epidemiological links, shared risk factors, and mutual influences of clinical management strategies in the comorbidity of diabetes and PC and focus on dissecting the pivotal role of autophagy at the intersection of their mechanisms. To elucidate the connection of autophagy pathways in both diseases, we aimed to provide novel perspectives on their common pathophysiological basis and identify potential targets for innovative therapeutic strategies against this comorbidity.
1 Background
Diabetes mellitus is a global metabolic disorder characterized by chronic hyperglycemia, primarily arising from insulin secretion deficiency due to pancreatic β-cell dysfunction and insulin resistance in peripheral tissues (1). According to the latest data from the International Diabetes Federation (IDF), the global diabetic population exceeds 537 million and is projected to rise to 783 million by 2045, with type 2 diabetes mellitus (T2DM) accounting for over 90% of cases (2). Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), ranks among the most lethal digestive tract malignancies, with a five-year survival rate of approximately 10% (3). It is projected to become the second leading cause of cancer-related deaths by 2030 (4). Pancreatic cancer onset is insidious, early diagnosis is challenging, and most patients are diagnosed at advanced stages, missing the window for curative surgery.
Clinical observations have long noted a close association between diabetes and pancreatic cancer. This relationship is bidirectional: on one hand, long-term T2DM (>5 years) is a well-established risk factor for pancreatic cancer, increasing the risk by 1.5 to 2.0-fold, and up to 50%-80% of pancreatic cancer patients present with hyperglycemia or new-onset diabetes at diagnosis, the latter often considered a paraneoplastic syndrome or early sign of pancreatic cancer (5–7). This comorbidity suggests shared upstream pathogenic mechanisms. Traditionally, chronic inflammation, hyperinsulinemia, and activation of the insulin-like growth factor-1 (IGF-1) signaling pathway have been considered to link diabetes and pancreatic cancer (8–12). In recent years, the crucial role of autophagy, a fundamental cellular homeostatic regulatory mechanism, has been increasingly revealed.
Autophagy is an evolutionarily conserved process in eukaryotic cells that involves the degradation of damaged organelles, misfolded proteins, and pathogens via lysosomes (13, 14). The mode of substrate delivery to lysosomes can be categorized into macroautophagy, microautophagy, and chaperone-mediated autophagy, with the term “autophagy” commonly referred to as macroautophagy (15). Basal autophagy is essential for maintaining cellular health, particularly in metabolically active and stress-prone cells such as pancreatic β-cells. In diabetes, dysfunctional autophagy leads to the accumulation of damaged mitochondria and endoplasmic reticulum (ER) in β-cells, triggering oxidative stress and ER stress and ultimately promoting β-cell apoptosis and insulin secretion defects (16, 17). An imbalance in insulin of autophagy target tissues also exacerbates insulin resistance (18). In pancreatic cancer, the role of autophagy is more complex and context-dependent. During the precancerous lesion stage, autophagy acts as a tumor suppressor by clearing damaged components and suppressing inflammation; however, in established pancreatic tumors, cancer cells harness autophagy to cope with metabolic stresses such as nutrient deprivation, hypoxia, and chemotherapy, whereby autophagy activation supports tumor proliferation, invasion, metastasis, and drug resistance (19–21). We propose that, autophagy emerges is a key molecule connecting the metabolic dysregulation of diabetes with the malignant biology of pancreatic cancer. In-depth exploration of the dynamic changes and regulatory networks associated with comorbidities has significant theoretical and clinical implications for disease prevention, early diagnosis, and combination therapy.
2 Bidirectional associations between diabetes duration, glycemic control, and pancreatic cancer risk
The epidemiological association between diabetes and pancreatic cancer has been confirmed by numerous prospective cohort studies, case-control studies, and meta-analyses. A large cohort study involving over 1 million Asian individuals reported a summary relative risk (RR) of pancreatic cancer of 1.76 among diabetic patients, with the risk increasing with the duration of diabetes (22). The association between new-onset diabetes (within 3 years of diagnosis) and pancreatic cancer risk is particularly strong, with RRs as high as 2.0 to 2.5, strongly suggesting that new-onset diabetes may be an early clinical manifestation of pancreatic cancer (23). It is notable that the endocrine and exocrine pancreases share a common vascular bed. Through this shared vasculature, soluble factors can mediate pathogenic cross-talk between the two compartments (24). For example, TGF-β signaling upregulated during PDAC progression may traverse this network and contribute to β-cell exhaustion (25).
In addition to duration, the treatment modality for diabetes is also associated with pancreatic cancer risk, providing indirect evidence for a causal relationship. Multiple retrospective studies have shown that long-term metformin use is associated with a reduced risk of pancreatic cancer, potentially mediated by metformin’s activation of AMP-activated protein kinase (AMPK) and inhibition of mammalian target of rapamycin (mTOR) signaling by metformin, thereby modulating autophagy (26–28). Conversely, some studies suggest that long-term use of exogenous insulin or insulin secretagogues may slightly increase pancreatic cancer risk, possibly because hyperinsulinemia persistently activates the insulin/IGF-1 receptor pathway and promotes cell proliferation (28, 29). However, whether these associations are subject to bias and their definitive causality require further prospective validation.
From the perspective of pancreatic cancer, diabetic patients constitute a significant proportion of pancreatic cancer patients. Pooled analyses indicate that approximately 25%-50% of pancreatic cancer patients have comorbid diabetes, with approximately 40%-50% being newly diagnosed within the preceding three years (6, 30–32). Pancreatic cancer patients with comorbid diabetes often have a poorer prognosis and shorter overall survival (33). This may be attributed to multiple factors, including a hyperglycemic environment promoting tumor progression, diabetic microvascular complications limiting the full application of chemotherapy, and generally poorer overall health status in the comorbid state (34–36). Furthermore, genetic epidemiological studies have revealed that certain polymorphisms associated with diabetes and insulin resistance are also linked to pancreatic cancer susceptibility, supporting the notion that these two diseases share part of their genetic background (37, 38).
In summary, robust epidemiological evidence has established a close association between diabetes (particularly new-onset diabetes) and pancreatic cancer. This relationship manifests not only in diabetes being a risk factor for pancreatic cancer but also in pancreatic cancer-induced diabetes. This bidirectional interplay points to an interaction in their pathophysiological mechanisms, we propose that autophagy is a common pathway that likely plays a critical role.
3 Role of autophagy dysfunction in linking diabetes to pancreatic cancer pathogenesis
As a core homeostatic regulatory mechanism, autophagy plays an indispensable role in maintaining normal pancreatic physiology. The pancreas, which performs both exocrine (digestive enzyme secretion) and endocrine (insulin, glucagon secretion) functions, comprises highly metabolically active and stress-prone cell types—acinar cells and pancreatic β-cells—that critically rely on autophagy to clear damaged components and maintain function (39, 40). In diabetes, disrupted autophagy is involved in the core pathologies of β-cell failure and insulin resistance (18, 41); in pancreatic cancer, autophagy involves a complex biological mechanisms, acting as a potential tumor suppressor mechanism and a survival dependency for established tumors (42). It is worth noting that the dysregulation of autophagy is increasingly regarded as a key mechanism connecting the risk factors for diabetes and pancreatic cancer. In this section, we systematically explore the specific role of autophagy in the pathogenesis of diabetes and pancreatic cancer, and elucidate its function as a molecular connection linking these two diseases in their comorbid context (Figure 1).
Figure 1. The Dual Role of Autophagy in Linking Type 2 Diabetes and Pancreatic Cancer Pathogenesis. (A) Impaired autophagy leads to disruption of β-cell homeostasis. (B) Dysregulated autophagy causes glucose metabolic dysregulation in insulin target tissues. (C) Autophagic dysfunction drives diabetic complications. (D) Dual role of autophagy in pancreatic tumorigenesis and progression. (E) Core process of autophagy.
3.1 Impaired autophagy as a pathogenic driver of diabetes
The role of autophagy in diabetes is tissue and cell-specific, with its function in pancreatic β-cells being the most extensively studied. β-cells are responsible for sensing blood glucose levels and precisely secreting insulin; their functional integrity is crucial for maintaining glucose homeostasis (43). Basal autophagy is essential for β-cell survival and function. Mice with β-cell-specific knockout of the essential autophagy gene Atg7 exhibit reduced β-cell mass, abnormal insulin secretory granules, defective insulin secretion, and ultimately develop overt diabetes (44). Evidence of impaired autophagic flux, including accumulated autophagosomes and reduced lysosomal function, has also been observed in islets from human T2DM patients (45). Under metabolic stress from high glucose and lipids (glucolipotoxicity), ER stress and oxidative stress intensify within β-cells, generating abundant misfolded proteins and damaged mitochondria (46). A fully functional autophagic system is crucial under these conditions to clear these harmful substances and maintain cell survival. If autophagy is deficient, stress signals persist, eventually triggering β-cell apoptosis.
In addition to β-cells, autophagy plays key roles in insulin-target tissues. In the liver, autophagy participates in regulating glycogen metabolism and gluconeogenesis. During starvation, autophagy is activated, degrading intracellular components to produce precursors like amino acids for gluconeogenesis, thereby maintaining blood glucose (47). In insulin-resistant states, hepatic autophagy may become dysregulated, contributing to abnormal hepatic glucose output (48). In skeletal muscle and adipose tissue, autophagy also participates in metabolic regulation. Research indicates that autophagy function is altered in skeletal muscle and adipocytes under conditions of obesity and insulin resistance, potentially through the activation of inflammatory signaling pathways (49, 50). For example, inflammatory cytokines like tumor necrosis factor-s (TNF-α) can inhibit autophagy, and autophagy inhibition can further exacerbate inflammation, creating a vicious cycle that exacerbates insulin sensitivity (51).
Autophagy is also closely involved in the development and progression of diabetic complications. In diabetic nephropathy, impaired autophagy in glomerular podocytes in high-glucose environments leads to cell injury and proteinuria, accelerating nephropathy progression (52). In diabetic retinopathy, dysregulated autophagy in retinal pericytes similarly contributes to vascular damage (53). Therefore, modulating autophagy has emerged as a potential novel strategy for treating diabetes and its complications. For example, some of the beneficial effects of metformin are attributed to its activation of AMPK, which thereby mildly enhances autophagy (54). Rapamycin (an mTOR inhibitor) is a potent autophagy inducer, but its systemic side effects limit clinical application (55). Identifying more precise means of autophagy modulating is a research direction.
This section details the multifaceted roles of autophagy in diabetes. From preserving βreser function to modulating metabolism in insulin-targeted tissues and contributing to various complications, autophagy is critically involved at multiple pathophysiological levels. This widespread involvement underscores that autophagy dysfunction is a common thread linking diverse diabetic pathologies.
3.2 Dual role of autophagy in pancreatic tumorigenesis and progression
In pancreatic cancer, autophagy plays a seemingly paradoxical role, and its function is highly dependent on the stage of tumor development and the microenvironment.
In the early stages of pancreatic cancer development, autophagy primarily acts as a tumor suppressor. Mutations in the oncogene Kirsten rat sarcoma virus (KRAS) are the most common and critical initiating event in pancreatic cancer and are found in more than 90% of PDAC cases (56). At the precancerous lesion stage, activated KRAS initially promotes autophagy, likely as a cell-autonomous adaptation mechanism to clear metabolic waste and damaged organelles generated by KRAS-driven proliferation, thereby maintaining cellular homeostasis and preventing genomic instability. Inhibiting autophagy at this stage accelerates KRAS-driven pancreatic intraepithelial neoplasia (PanIN) progression to invasive carcinoma (57). Furthermore, deletion of autophagy-related genes has been shown to promote pancreatic inflammation and fibrosis, creating a microenvironment favorable for tumorigenesis (57, 58).
However, once pancreatic cancer is fully established and progresses to advanced stages, the role of autophagy shifts from beneficial to harmful. Advanced pancreatic cancer is characterized defined by an extremely desolate tumor microenvironment: dense fibrotic stroma and poor vascular supply lead to severe nutrient and oxygen deprivation (59). Under these extreme stress conditions, the survival of cancer cells relies heavily on autophagy. Autophagy sustains cancer cells by degrading intracellular macromolecules, providing basic raw materials necessary for maintaining essential metabolism, biosynthesis, and energy production, thereby supporting their survival and growth in harsh environments (60). Numerous preclinical studies have confirmed that inhibiting autophagy, either genetically or pharmacologically, in established pancreatic cancer models, suppresses tumor growth and synergizes with standard chemotherapies such as gemcitabine, enhancing anti-tumor effects (61–63).
Autophagy is also a key mechanism of chemotherapy resistance in pancreatic cancer. Chemotherapeutic agents themselves represent strong stressors to cancer cells and can induce autophagy. Cancer cells exploit this induced autophagy to “digest” the damage inflicted by the drugs, evading apoptosis and thus developing resistance (64). Consequently, the combination of autophagy inhibitors is considered a promising strategy to overcome chemotherapy resistance in pancreatic cancer. Currently, several clinical trials are evaluating hydroxychloroquine combined with chemotherapy in pancreatic cancer, but the results suggest that targeting autophagy alone may be insufficient for significant efficacy, necessitating the use of more specific inhibitors or rational combination regimens in the future (65, 66). Moreover, to avoid off-target damage to islet β-cells from autophagy inhibition, two critical strategies can be pursued. First, autophagy modulators that specifically target the tumor microenvironment should be developed. Second, refined patient stratification in clinical practice based on islet functional reserve and tumor autophagy dependence should be implemented.
Pancreatic stellate cells (PSCs) are the primary source of the fibrotic microenvironment in pancreatic cancer (67). Recent research has revealed that PSCs in the microenvironment of pancreatic cancer are predominantly in an activated state, and their autophagy levels are also significantly increased. These findings indicate that tumor-stromal interactions can effectively activate autophagy in PSCs, thereby accelerating pancreatic fibrosis and further promoting the development and metastasis of pancreatic cancer. Inhibiting autophagy in PSCs may help remodel the tumor microenvironment, enhancing drug delivery and efficacy (68). This finding reveals that in addition to targeting tumor cells themselves, modulating autophagy in non-tumor cells within the tumor microenvironment is also a potential therapeutic avenue.
In summary, the role of autophagy in pancreatic cancer evolves from tumor suppression to tumor promotion with disease progression. Initially protective, it becomes a key survival mechanism in advanced stages, supporting cancer cells through catabolism and mediating therapy resistance. Thus, understanding this dynamic regulation is crucial for developing stage-specific therapeutic strategies.
3.3 Autophagy dysregulation in comorbidity pathogenesis
The comorbidity of diabetes and pancreatic cancer arises from interactions of multiple pathophysiological bases, involving a complex network of genetic susceptibility, metabolic dysregulation, and environmental exposures. Recent research suggests that dysregulation of the autophagic process may be the primary cause of these risk factors for the development of both diseases. A deep understanding of this mechanism is crucial for identifying high-risk populations and enabling early intervention.
Age is the most prominent risk factor for comorbidities, with the incidence risk steadily increasing with age, peaking particularly in individuals over 65 years of age (69). Sex differences are also evident, with males exhibiting greater susceptibility to both pancreatic cancer and T2DM (70). Studies indicate that an age-related decline in autophagic function may exacerbate metabolic stress and genomic instability in pancreatic tissue, thereby creating a common ground for the onset of both diseases (41).
Obesity, particularly central obesity, is the central metabolic connecting the two diseases, promoting their development through multiple mechanisms. Visceral adipose tissue overrelease free fatty acids, proinflammatory cytokines (including TNF-α and IL-6), and dysregulated adipokines (manifested as increased leptin and decreased adiponectin levels), collectively establishing a state of chronic low-grade inflammation (71–73). This metabolic inflammatory environment not only promotes diabetes progression by inducing insulin resistance and β-cell dysfunction but also fosters a protumor microenvironment by activating key signaling pathways such as nuclear factor kappa-B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) (72, 74–76). Obesity-related metabolic pressure significantly alters autophagic activity—on the one hand, nutrient excess may suppress basal autophagy in insulin-sensitive tissues, exacerbating metabolic disorders; on the other hand, tumor cells may exploit autophagy to cope with nutrient scarcity and oxidative stress, increasing survival (60, 77).
Dietary and lifestyle factors influence disease risk through direct and indirect pathways. Long-term adherence to a Western diet pattern, high in fat, sugar, red meat, and processed meats, not only promotes obesity and metabolic abnormalities but can also alter the gut microbiota composition and increase intestinal permeability, leading to endotoxin entry into the bloodstream and further amplifying systemic inflammation (78, 79). This chronic inflammatory state interferes with the normal regulation of autophagy, placing pancreatic cells under persistent metabolic stress. Smoking, the most well-defined environmental risk factor for pancreatic cancer, involves carcinogens that directly cause DNA damage and disrupt the functional integrity of the autophagy-lysosome pathway, leading to abnormal protein aggregation and mitochondrial dysfunction (80). Alcohol intake primarily acts by inducing chronic pancreatitis, a well-established risk factor, while dysregulated autophagy during the continuous cycle of pancreatic injury and repair both accelerates endocrine failure leading to diabetes and creates favorable conditions for tumorigenesis (80).
With respect to genetic background, genome-wide association studies (GWASs) have identified several loci associated with the risk of both diseases. Transcription factor 7-like 2 (TCF7L2), one of the strongest genetic determinants of T2DM, has specific variants that are also associated with an increased risk of pancreatic cancer (81). Notably, conflicting evidence from in vitro experiments has shown that this gene plays a dual role in maintaining glucose homeostasis and regulating pancreatic epithelial cell proliferation and differentiation by modulating the Wnt signaling pathway and islet β-cell function (82, 83). Studies have shown that, TCF7L2 also participates in the regulation of autophagy, which may be a potential mechanism underlying its influence on the risk of both diseases (84). Furthermore, carriers of pancreatic cancer susceptibility genes such as BRCA1/2, PALB2, CDKN2A, and ATM not only have increased tumor risk but also the potential functions of these genes in metabolic pathways and autophagy regulation warrant further exploration (85).
Chronic pancreatitis serves is a critical connection between these two diseases. Persistent inflammatory damage and tissue repair processes lead to pancreatic fibrosis and acinar cell loss (86). In this pathological process, autophagy plays a complex dual role—moderate autophagy activation helps cells cope with metabolic stress, whereas sustained dysregulation of autophagy accelerates the destruction of the pancreatic parenchyma (87). Research indicates that autophagy abnormalities in chronic pancreatitis may simultaneously promote endocrine failure and tumorigenesis, acting as a significant driving factor of comorbidity (88, 89).
In summary, age, sex, obesity, poor diet, smoking, alcohol consumption, genetic background, and chronic pancreatitis collectively constitute the risk network for diabetes-pancreatic cancer comorbidity. These factors, by driving common downstream pathways including chronic inflammation, oxidative stress, metabolic disorders, and autophagic imbalance, form the pathological basis promoting the development and progression of both diseases. Notably, the bidirectional blood flow between the pancreatic acini and islets also provides an anatomical basis for these factors to simultaneously affect tumor cells and β cells (24). Among these, we argue that autophagy is the core mechanism for cellular quality control and metabolic adaptation, whose functional disruption may be the pathway connecting various risk factors to disease onset, offering new targets and insights for the prevention and early intervention of comorbidities.
4 Integrated therapeutic strategies for diabetes and pancreatic cancer comorbidity
The clinical management of diabetes and pancreatic cancer comorbidity presents a complex challenge, requiring a multidisciplinary team approach involving oncology, endocrinology, nutrition, and surgery to balance glycemic control with the efficacy and safety of antitumor therapy. Treatment strategies must be highly individualized, comprehensively considering pancreatic cancer stage, resectability, diabetes type and duration, existing complications, and the patient’s overall condition (Table 1).
Table 1. Drug therapy in the comorbidities of diabetes and pancreatic cancer.
Surgical resection remains the only potentially curative treatment for pancreatic cancer. For patients with resectable or borderline resectable pancreatic cancer comorbid with diabetes, perioperative glycemic management is paramount. Strict target glycemic control (7.8-10.0 mmol/L) helps reduce the risk of complications such as surgical site infections and anastomotic leaks (90). Pancreatic cancer surgery itself can further impair pancreatic endocrine and exocrine function, inducing or worsening diabetes, i.e., pancreatogenic diabetes (91). Therefore, close postoperative blood glucose monitoring and timely adjustment of hypoglycemic regimens are essential.
For patients with advanced pancreatic cancer, chemotherapy remains the cornerstone of treatment. Clinical cohort studies have demonstrated that common regimens such as gemcitabine, FOLFIRINOX, and nab-paclitaxel combinations, while targeting cancer cells, also impact the autophagic process through various pathways (92, 93). Gastrointestinal side effects induced by these chemotherapeutic agents can lead to reduced nutritional intake, not only increasing the risk of hypoglycemia but also altering cellular metabolic states and affecting autophagic flux (92). Consequently, during chemotherapy, alongside adjusting hypoglycemic regimens to mitigate hypoglycemia risk, attention must be given to the comprehensive impact of these drugs on autophagy pathways.
In the selection of hypoglycemic agents, careful consideration should be given to their modulatory effects on autophagy and potential synergy with antitumor therapies. Metformin, as the first-line treatment for T2DM, exerts its antitumor effects closely related to autophagy regulation—by activating AMPK and inhibiting mTOR signaling, it induces protective autophagy and suppresses tumor cell proliferation (27, 54, 94). Multiple retrospective studies indicate a survival benefit for diabetic patients with pancreatic cancer using metformin, potentially partly attributable to its enhancement of chemotherapy sensitivity via autophagic mechanisms (28, 95). Controversies regarding the pancreatic safety of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors have been largely addressed by large cardiovascular outcome trials, and their modulatory effects on autophagy are emerging as a new research focus (96–102). Sodium-glucose transporter 2 (SGLT2) inhibitors, while having a low risk of hypoglycemia, warrant vigilance for potential ketoacidosis, especially during reduced oral intake due to chemotherapy, as this metabolic state significantly influences autophagy levels (103). Insulin therapy should adhere to the principles of precision and moderation, avoiding potential tumor-promoting risks associated with hyperinsulinemia, while also noting the inhibitory effects of insulin on cellular autophagy (8, 104, 105).
Targeting autophagy represents a new frontier in pancreatic cancer research. Autophagy inhibitors such as hydroxychloroquine (HCQ) have been combined with chemotherapeutic agents such as gemcitabine in clinical trials for advanced pancreatic cancer (65). The rationale is to prevent tumor cells from utilizing autophagy to resist chemotherapeutic stress, thereby “starving” cancer cells. However, early clinical trial outcomes have been mixed. Several plausible explanations include: insufficient autophagy suppression in patient tumors by HCQ, the dual role of autophagy inhibition in suppressing tumor metabolism and proliferation while potentially promoting metastasis, and the current lack of suitable pharmacodynamic biomarkers (66, 106, 107). These directions may involve the development of more specific autophagy inhibitors or the exploration of combinations of autophagy modulators with immunotherapy and targeted therapy. For patients with diabetes comorbid with pancreatic cancer, coordinating the interaction between hypoglycemic drugs (e.g., metformin, an autophagy inducer) and autophagy inhibitors (e.g., HCQ) presents a novel clinical challenge (108). In summary, we argue that managing diabetes-pancreatic cancer comorbidity requires an integrated, dynamically adjusted strategy that controls metabolic disturbances while maximizing antitumor efficacy and improving patient quality of life.
5 Summary
The comorbidity of diabetes and pancreatic cancer represents a significant global health challenge driven by interconnected pathophysiological mechanisms. We review epidemiological, clinical, and risk factor evidence, highlighting autophagy as a central biological pathway linking these conditions.
Epidemiological studies establish diabetes—particularly new-onset cases—as both a risk factor and potential early indicator of pancreatic cancer, while pancreatic cancer frequently induces diabetes (5). This bidirectional relationship necessitates clinical vigilance in both directions. Therapeutically, management requires integrated strategies where antidiabetic treatments must be evaluated for their impact on tumor outcomes and anticancer therapies for their metabolic consequences.
Mechanistically, autophagy serves as a critical nexus. In diabetes, its impairment contributes to β-cell dysfunction and insulin resistance (40); in pancreatic cancer, it plays a context-dependent role in tumor suppression and promotion (42). Shared risk factors including obesity and chronic inflammation converge through autophagy dysregulation, creating a permissive environment for tumor development when combined with oncogenic mutations such as KRAS (56).
Key unanswered questions remain regarding the temporal dynamics of autophagy during disease progression, reliable biomarkers for risk stratification, and context-specific therapeutic modulation of autophagic pathways. We propose that addressing these issues through mechanistic studies and innovative trial designs will be essential for developing effective prevention, diagnostic, and therapeutic strategies targeting this lethal comorbidity.
Author contributions
LL: Writing – original draft, Project administration, Conceptualization. YC: Writing – original draft, Visualization. SW: Writing – review & editing. WD: Writing – original draft. TL: Writing – original draft. FC: Writing – review & editing, Visualization. GY: Visualization, Writing – review & editing. WC: Writing – original draft. XL: Writing – review & editing. CL: Writing – review & editing, Supervision. XX: Supervision, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the National Natural Science Foundation of China (82574658); the State Key Laboratory of Dampness Syndrome of Chinese Medicine Research Foundation (SZ2022QN02); Science and Technology Projects in Guangzhou (2025A03J2629, 2024A03J0057, 2023A03J0230 & 202201020351); Excellent Academic Papers Support Program of Guangdong Provincial Hospital of Chinese Medicine (SZY2023029); Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0502600 & 2023ZD0502601); and the TCM Research Fund of Guangdong Provincial Hospital of Chinese Medicine (YN2024GZRPY051).
Conflict of interest
The authors declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
AMPK, AMP-activated protein kinase; DPP-4, dipeptidyl peptidase 4; ER, endoplasmic reticulum; GLP-1, glucagon-like peptide-1; HCQ, hydroxychloroquine; IDF, International Diabetes Federation; IGF-1, insulin-like growth factor-1; KRAS, Kirsten rat sarcoma virus; mTOR, mammalian target of rapamycin; NF-κB, Nuclear Factor Kappa-β; PanIN, pancreatic intraepithelial neoplasia; PDAC, pancreatic ductal adenocarcinoma; PSCs, pancreatic stellate cells; RR, relative risk; SGLT2, Sodium-glucose transporter 2; STAT3, signal transducer and activator of transcription 3; T2DM, type 2 diabetes mellitus; TCF7L2, transcription factor 7-like 2; TNF-α, tumor necrosis factor-α.
References
1. Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. (2010) 33:S62–S9. doi: 10.2337/dc10-S062
3. Kamisawa T, Wood LD, Itoi T, and Takaori K. Pancreatic cancer. Lancet (London England). (2016) 388:73–85. doi: 10.1016/S0140-6736(25)00261-2
4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, and Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. (2014) 74:2913–21. doi: 10.1158/0008-5472.CAN-14-0155
5. Sah RP, Nagpal SJ, Mukhopadhyay D, and Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol hepatology. (2013) 10:423–33. doi: 10.1038/nrgastro.2013.49
6. Pannala R, Basu A, Petersen GM, and Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. (2009) 10:88–95. doi: 10.1016/S1470-2045(08)70337-1
7. Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, et al. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Institute. (2013) 105:1027–35. doi: 10.1093/jnci/djt123
8. Zhang AMY, Magrill J, de Winter TJJ, Hu X, Skovsø S, Schaeffer DF, et al. Endogenous hyperinsulinemia contributes to pancreatic cancer development. Cell Metab. (2019) 30:403–4. doi: 10.1016/j.cmet.2019.07.003
9. Colmers IN, Bowker SL, Tjosvold LA, and Johnson JA. Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Diabetes Metab. (2012) 38:485–506. doi: 10.1016/j.diabet.2012.08.011
10. Chen G, Tan C, Liu X, Wang X, Tan Q, and Chen Y. Associations between systemic immune-inflammation index and diabetes mellitus secondary to pancreatic ductal adenocarcinoma. J Clin Med. (2023) 12:756. doi: 10.3390/jcm12030756
11. Lopez T and Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. (2002) 1:339–53. doi: 10.1016/S1535-6108(02)00055-7
12. Donath MY and Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. (2011) 11:98–107. doi: 10.1038/nri2925
13. Dikic I and Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. (2018) 19:349–64. doi: 10.1038/s41580-018-0003-4
14. Klionsky DJ. Autophagy revisited: a conversation with Christian de Duve. Autophagy. (2008) 4:740–3. doi: 10.4161/auto.6398
15. Yang Z and Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol. (2010) 12:814–22. doi: 10.1038/ncb0910-814
16. Bachar-Wikstrom E, Wikstrom JD, Kaiser N, Cerasi E, and Leibowitz G. Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy. (2013) 9:626–8. doi: 10.4161/auto.23642
17. Bugliani M, Mossuto S, Grano F, Suleiman M, Marselli L, Boggi U, et al. Modulation of autophagy influences the function and survival of human pancreatic beta cells under endoplasmic reticulum stress conditions and in type 2 diabetes. Front endocrinology. (2019) 10:52. doi: 10.3389/fendo.2019.00052
18. Yang Y, Qiu W, Xiao J, Sun J, Ren X, and Jiang L. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway. J Trans Med. (2024) 22:309. doi: 10.1186/s12967-024-05060-7
19. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. (2006) 10:51–64. doi: 10.1016/j.ccr.2006.06.001
20. Rosenfeldt MT, O’Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature. (2013) 504:296–300. doi: 10.1038/nature12865
21. Hu F, Song D, Yan Y, Huang C, Shen C, Lan J, et al. IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation. Nat Commun. (2021) 12:3651. doi: 10.1038/s41467-021-23923-1
22. Ansary-Moghaddam A, Huxley R, Barzi F, Lawes C, Ohkubo T, Fang X, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer epidemiology Biomarkers Prev. (2006) 15:2435–40. doi: 10.1158/1055-9965.EPI-06-0368
23. Everhart J and Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Jama. (1995) 273:1605–9.
24. Dybala MP, Kuznetsov A, Motobu M, Hendren-Santiago BK, Philipson LH, Chervonsky AV, et al. Integrated pancreatic blood flow: bidirectional microcirculation between endocrine and exocrine pancreas. Diabetes. (2020) 69:1439–50. doi: 10.2337/db19-1034
25. Parajuli P, Nguyen TL, Prunier C, Razzaque MS, Xu K, and Atfi A. Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells. Life Sci alliance. (2020) 3:e201900573. doi: 10.26508/lsa.201900573
26. Hu H, Fang Y, Zhou X, Gong L, L-l L, Wang W, et al. Relationship of metformin with the risk of pancreatic cancer in patients with type 2 diabetes: a meta-analysis. .Biomedical Research-tokyo. (2017) 28:4439–44.
27. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Trans Oncol. (2013) 6:649–59. doi: 10.1593/tlo.13556
28. Currie CJ, Poole CD, and Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. (2009) 52:1766–77. doi: 10.1007/s00125-009-1440-6
29. Yang J, Waldron RT, Su HY, Moro A, Chang HH, Eibl G, et al. Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells. Am J Physiol Gastrointestinal liver Physiol. (2016) 311:G675–g87. doi: 10.1152/ajpgi.00251.2016
30. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, and Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. (2008) 134:981–7. doi: 10.1053/j.gastro.2008.01.039
31. Aggarwal G, Kamada P, and Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas. (2013) 42:198–201. doi: 10.1097/MPA.0b013e3182592c96
32. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. (2008) 134:95–101. doi: 10.1053/j.gastro.2007.10.040
33. Shen H, Zhan M, Wang W, Yang D, and Wang J. Impact of diabetes mellitus on the survival of pancreatic cancer: a meta-analysis. OncoTargets Ther. (2016) 9:1679–88. doi: 10.2147/OTT.S95744
34. Zhu X, Xu H, Xiao Z, Liu H, Ni Q, Yu X, et al. Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Endocrine. (2023) 79:296–303. doi: 10.1007/s12020-022-03196-4
35. Jeon CY, Li D, Cleary S, Stolzenberg-Solomon R, Bosetti C, La Vecchia C, et al. The association of recently diagnosed diabetes and long-term diabetes with survival in pancreatic cancer patients: A pooled analysis. Pancreas. (2018) 47:314–20. doi: 10.1097/MPA.0000000000000989
36. Hilmi M, Ederhy S, Waintraub X, Funck-Brentano C, Cohen A, Vozy A, et al. Cardiotoxicity associated with gemcitabine: literature review and a pharmacovigilance study. Pharm (Basel Switzerland). (2020) 13:325. doi: 10.3390/ph13100325
37. Hu Y, Zeng N, Ge Y, Wang D, Qin X, Zhang W, et al. Identification of the shared gene signatures and biological mechanism in type 2 diabetes and pancreatic cancer. Front endocrinology. (2022) 13:847760. doi: 10.3389/fendo.2022.847760
38. Duvillié B, Kourdoughli R, Druillennec S, Eychène A, and Pouponnot C. Interplay between diabetes and pancreatic ductal adenocarcinoma and insulinoma: the role of aging, genetic factors, and obesity. Front endocrinology. (2020) 11:563267. doi: 10.3389/fendo.2020.563267
39. Zhou Q and Melton DA. Pancreas regeneration. Nature. (2018) 557:351–8. doi: 10.1038/s41586-018-0088-0
40. Choi SE, Lee SM, Lee YJ, Li LJ, Lee SJ, Lee JH, et al. Protective role of autophagy in palmitate-induced INS-1 beta-cell death. Endocrinology. (2009) 150:126–34. doi: 10.1210/en.2008-0483
41. Kitada M and Koya D. Autophagy in metabolic disease and ageing. Nat Rev Endocrinology. (2021) 17:647–61. doi: 10.1038/s41574-021-00551-9
42. Li J, Chen X, Kang R, Zeh H, Klionsky DJ, and Tang D. Regulation and function of autophagy in pancreatic cancer. Autophagy. (2021) 17:3275–96. doi: 10.1080/15548627.2020.1847462
43. Al-Kuraishy HM, Jabir MS, Al-Gareeb AI, Klionsky DJ, and Albuhadily AK. Dysregulation of pancreatic β-cell autophagy and the risk of type 2 diabetes. Autophagy. (2024) 20:2361–72. doi: 10.1080/15548627.2024.2367356
44. Quan W, Hur KY, Lim Y, Oh SH, Lee JC, Kim KH, et al. Autophagy deficiency in beta cells leads to compromised unfolded protein response and progression from obesity to diabetes in mice. Diabetologia. (2012) 55:392–403. doi: 10.1007/s00125-011-2350-y
45. Zummo FP, Cullen KS, Honkanen-Scott M, Shaw JAM, Lovat PE, and Arden C. Glucagon-like peptide 1 protects pancreatic β-cells from death by increasing autophagic flux and restoring lysosomal function. Diabetes. (2017) 66:1272–85. doi: 10.2337/db16-1009
46. Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, et al. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med. (2014) 20:1417–26. doi: 10.1038/nm.3705
47. Ezaki J, Matsumoto N, Takeda-Ezaki M, Komatsu M, Takahashi K, Hiraoka Y, et al. Liver autophagy contributes to the maintenance of blood glucose and amino acid levels. Autophagy. (2011) 7:727–36. doi: 10.4161/auto.7.7.15371
48. Yang L, Li P, Fu S, Calay ES, and Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. (2010) 11:467–78. doi: 10.1016/j.cmet.2010.04.005
49. Soussi H, Reggio S, Alili R, Prado C, Mutel S, Pini M, et al. DAPK2 downregulation associates with attenuated adipocyte autophagic clearance in human obesity. Diabetes. (2015) 64:3452–63. doi: 10.2337/db14-1933
50. Pan Y, Yang XH, Guo LL, Gu YH, Qiao QY, and Jin HM. Erythropoietin Reduces Insulin Resistance via Regulation of Its Receptor-Mediated Signaling Pathways in db/db Mice Skeletal Muscle. Int J Biol Sci. (2017) 13:1329–40. doi: 10.7150/ijbs.19752
51. Sadeghi A, Niknam M, Momeni-Moghaddam MA, Shabani M, Aria H, Bastin A, et al. Crosstalk between autophagy and insulin resistance: evidence from different tissues. Eur J Med Res. (2023) 28:456. doi: 10.1186/s40001-023-01424-9
52. Lenoir O, Jasiek M, Hénique C, Guyonnet L, Hartleben B, Bork T, et al. Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis. Autophagy. (2015) 11:1130–45. doi: 10.1080/15548627.2015.1049799
53. Lopes de Faria JM, Duarte DA, Montemurro C, Papadimitriou A, Consonni SR, and Lopes de Faria JB. Defective autophagy in diabetic retinopathy. Invest Ophthalmol Visual science. (2016) 57:4356–66. doi: 10.1167/iovs.16-19197
54. Ravindran S, Kuruvilla V, Wilbur K, and Munusamy S. Nephroprotective effects of metformin in diabetic nephropathy. J Cell Physiol. (2017) 232:731–42. doi: 10.1002/jcp.25598
55. Su DW, Mita M, and Mita AC. The clinical pharmacology and toxicity profile of rapalogs. In: Mita M, Mita A, and Rowinsky EK, editors. mTOR inhibition for cancer therapy: past, present and future, vol. p . Springer Paris, Paris (2016). p. 161–89.
56. Luo J. KRAS mutation in pancreatic cancer. Semin Oncol. (2021) 48:10–8. doi: 10.1053/j.seminoncol.2021.02.003
57. Görgülü K, Diakopoulos KN, Ai J, Schoeps B, Kabacaoglu D, Karpathaki AF, et al. Levels of the autophagy-related 5 protein affect progression and metastasis of pancreatic tumors in mice. Gastroenterology. (2019) 156:203–17.e20. doi: 10.1053/j.gastro.2018.09.053
58. Cao SS, Su AP, Du XJ, Li A, Hu WM, Zhang ZD, et al. The expressions and correlation of bcl-2 and Beclin-1 in pancreatic cancer. Sichuan da xue xue bao Yi xue ban = J Sichuan Univ Med Sci edition. (2012) 43:156–60.
59. Spivak-Kroizman TR, Hostetter G, Posner R, Aziz M, Hu C, Demeure MJ, et al. Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer. Cancer Res. (2013) 73:3235–47. doi: 10.1158/0008-5472.CAN-11-1433
60. Kundu M and Thompson CB. Autophagy: basic principles and relevance to disease. Annu Rev pathology. (2008) 3:427–55. doi: 10.1146/annurev.pathmechdis.2.010506.091842
61. Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, et al. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. (2019) 25:628–40. doi: 10.1038/s41591-019-0368-8
62. Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, et al. A unified approach to targeting the lysosome’s degradative and growth signaling roles. Cancer discovery. (2017) 7:1266–83. doi: 10.1158/2159-8290.CD-17-0741
63. Donohue E, Thomas A, Maurer N, Manisali I, Zeisser-Labouebe M, Zisman N, et al. The autophagy inhibitor verteporfin moderately enhances the antitumor activity of gemcitabine in a pancreatic ductal adenocarcinoma model. J Cancer. (2013) 4:585–96. doi: 10.7150/jca.7030
64. Chavez-Dominguez R, Perez-Medina M, Lopez-Gonzalez JS, Galicia-Velasco M, and Aguilar-Cazares D. The double-edge sword of autophagy in cancer: from tumor suppression to pro-tumor activity. Front Oncol. (2020) 10:578418. doi: 10.3389/fonc.2020.578418
65. Karasic TB, O’Hara MH, Loaiza-Bonilla A, Reiss KA, Teitelbaum UR, Borazanci E, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: A phase 2 randomized clinical trial. JAMA Oncol. (2019) 5:993–8. doi: 10.1001/jamaoncol.2019.0684
66. Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, et al. A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine/nab-paclitaxel in pancreatic cancer patients. Clin Cancer research: an Off J Am Assoc Cancer Res. (2020) 26:3126–34. doi: 10.1158/1078-0432.CCR-19-4042
67. Sherman MH. Stellate cells in tissue repair, inflammation, and cancer. Annu Rev Cell Dev Biol. (2018) 34:333–55. doi: 10.1146/annurev-cellbio-100617-062855
68. Endo S, Nakata K, Ohuchida K, Takesue S, Nakayama H, Abe T, et al. Autophagy is required for activation of pancreatic stellate cells, associated with pancreatic cancer progression and promotes growth of pancreatic tumors in mice. Gastroenterology. (2017) 152:1492–506.e24. doi: 10.1053/j.gastro.2017.01.010
69. Amri F, Belkhayat C, Yeznasni A, Koulali H, Jabi R, Zazour A, et al. Association between pancreatic cancer and diabetes: insights from a retrospective cohort study. BMC cancer. (2023) 23:856. doi: 10.1186/s12885-023-11344-w
70. Ilic M and Ilic I. Epidemiology of pancreatic cancer. World J gastroenterology. (2016) 22:9694–705. doi: 10.3748/wjg.v22.i44.9694
71. Halle M, Berg A, Northoff H, and Keul J. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exercise Immunol review. (1998) 4:77–94.
72. Nagaraju GP, Aliya S, and Alese OB. Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth factor Rev. (2015) 26:83–93. doi: 10.1016/j.cytogfr.2014.06.007
73. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. (2003) 112:1796–808. doi: 10.1172/JCI200319246
74. Hotamisligil GS, Shargill NS, and Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Sci (New York NY). (1993) 259:87–91. doi: 10.1126/science.7678183
75. Liu X, Tang R, Xu J, Tan Z, Liang C, Meng Q, et al. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Gut. (2023) 72:2329–43. doi: 10.1136/gutjnl-2022-329349
76. Taniguchi K and Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. (2018) 18:309–24. doi: 10.1038/nri.2017.142
77. Abdellatif M, Vasques-Nóvoa F, Ferreira JP, Sadoshima J, Diwan A, Linke WA, et al. NAD(+) repletion restores cardioprotective autophagy and mitophagy in obesity-associated heart failure by suppressing excessive trophic signaling. Autophagy. (2025) 21:2296–8. doi: 10.1080/15548627.2025.2522127
78. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. (2014) 63:116–24. doi: 10.1136/gutjnl-2012-304119
79. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. (2008) 57:1470–81. doi: 10.2337/db07-1403
80. Duell EJ. Epidemiology and potential mechanisms of tobacco smoking and heavy alcohol consumption in pancreatic cancer. Mol carcinogenesis. (2012) 51:40–52. doi: 10.1002/mc.20786
81. Weng C, Xi J, Li H, Cui J, Gu A, Lai S, et al. Single-cell lineage analysis reveals extensive multimodal transcriptional control during directed beta-cell differentiation. Nat Metab. (2020) 2:1443–58. doi: 10.1038/s42255-020-00314-2
82. Jin T. Current understanding on role of the wnt signaling pathway effector TCF7L2 in glucose homeostasis. Endocrine Rev. (2016) 37:254–77. doi: 10.1210/er.2015-1146
83. Takamoto I, Kubota N, Nakaya K, Kumagai K, Hashimoto S, Kubota T, et al. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia. (2014) 57:542–53. doi: 10.1007/s00125-013-3131-6
84. Wu Q, Ma J, Wei J, Meng W, Wang Y, and Shi M. lncRNA SNHG11 promotes gastric cancer progression by activating the wnt/β-catenin pathway and oncogenic autophagy. Mol therapy: J Am Soc Gene Ther. (2021) 29:1258–78. doi: 10.1016/j.ymthe.2020.10.011
85. Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. Jama. (2018) 319:2401–9. doi: 10.1001/jama.2018.6228
86. Kleeff J, Whitcomb DC, Shimosegawa T, Esposito I, Lerch MM, Gress T, et al. Chronic pancreatitis. Nat Rev Dis primers. (2017) 3:17060. doi: 10.1038/nrdp.2017.60
87. Gukovskaya AS, Gukovsky I, Algül H, and Habtezion A. Autophagy, inflammation, and immune dysfunction in the pathogenesis of pancreatitis. Gastroenterology. (2017) 153:1212–26. doi: 10.1053/j.gastro.2017.08.071
88. Li N, Wu X, Holzer RG, Lee JH, Todoric J, Park EJ, et al. Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice. J Clin Invest. (2013) 123:2231–43. doi: 10.1172/JCI64498
89. Iovanna JL. Autophagy induced during pancreatitis promotes KRAS-dependent transformation in the pancreas. Front Oncol. (2016) 6:226. doi: 10.3389/fonc.2016.00226
90. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. (2014) 37:1516–24. doi: 10.2337/dc13-1771
91. Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol hepatology. (2016) 1:226–37. doi: 10.1016/S2468-1253(16)30106-6
92. Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol hepatology. (2021) 6:128–38. doi: 10.1016/S2468-1253(20)30330-7
93. Marchand B, Poulin MA, Lawson C, Tai LH, Jean S, and Boucher MJ. Gemcitabine promotes autophagy and lysosomal function through ERK- and TFEB-dependent mechanisms. Cell Death discovery. (2023) 9:45. doi: 10.1038/s41420-023-01342-z
94. Ma T, Tian X, Zhang B, Li M, Wang Y, Yang C, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. (2022) 603:159–65. doi: 10.1038/s41586-022-04431-8
95. Xin W, Fang L, Fang Q, Zheng X, and Huang P. Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis. Mol Clin Oncol. (2018) 8:483–8. doi: 10.3892/mco.2017.1541
96. Liu Y, Tian Q, Yang J, Wang H, and Hong T. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes/metabolism Res Rev. (2018) 34:e3061. doi: 10.1002/dmrr.3061
97. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. New Engl J Med. (2013) 369:1317–26. doi: 10.1056/NEJMoa1307684
98. Xing C, Fan X, Liu M, Chen Y, Jia J, Li W, et al. Liraglutide inhibits autophagy to ameliorate post-cardiac arrest brain injury and ferroptosis in rats. Neurochemical Res. (2025) 50:161. doi: 10.1007/s11064-025-04412-z
99. Guo S, Li X, Liu M, Feng M, Wang X, Xue H, et al. Semaglutide alleviates ovarian oxidative stress and autophagy via the PI3K/AKT/mTOR pathway in mice with polycystic ovary syndrome. Drug design Dev Ther. (2025) 19:4297–310. doi: 10.2147/DDDT.S522730
100. Arab HH, Ashour AM, Gad AM, Mahmoud AM, and Kabel AM. Activation of AMPK/mTOR-driven autophagy and inhibition of NLRP3 inflammasome by saxagliptin ameliorate ethanol-induced gastric mucosal damage. Life Sci. (2021) 280:119743. doi: 10.1016/j.lfs.2021.119743
101. Jing Yin J, Bo Li Y, Ming Cao M, and Wang Y. Liraglutide improves the survival of INS-1 cells by promoting macroautophagy. Int J Endocrinol Metab. (2013) 11:184–90. doi: 10.5812/ijem.8088
102. Zummo FP, Krishnanda SI, Georgiou M, O’Harte FP, Parthsarathy V, Cullen KS, et al. Exendin-4 stimulates autophagy in pancreatic β-cells via the RAPGEF/EPAC-Ca(2+)-PPP3/calcineurin-TFEB axis. Autophagy. (2022) 18:799–815. doi: 10.1080/15548627.2021.1956123
103. Musso G, Saba F, Cassader M, and Gambino R. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ (Clinical Res ed). (2020) 371:m4147. doi: 10.1136/bmj.m4147
104. Gallagher EJ and LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. (2020) 20:629–44. doi: 10.1038/s41568-020-0295-5
105. Liu HY, Han J, Cao SY, Hong T, Zhuo D, Shi J, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. (2009) 284:31484–92. doi: 10.1074/jbc.M109.033936
106. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. oncologist. (2014) 19:637–8. doi: 10.1634/theoncologist.2014-0086
107. Yang J, Liu Y, and Liu S. The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion. Cell Death Disease. (2023) 14:506. doi: 10.1038/s41419-023-06032-3
Keywords: autophagy, comorbidity, diabetes mellitus, molecular mechanism, pancreatic cancer
Citation: Li L, Chen Y, Wang S, Du W, Lao T, Chen F, Yao G, Chen W, Li X, Liu C and Xue X (2026) Dysregulated autophagy at the nexus of type 2 diabetes mellitus and pancreatic cancer pathogenesis. Front. Endocrinol. 16:1735726. doi: 10.3389/fendo.2025.1735726
Received: 03 November 2025; Accepted: 15 December 2025; Revised: 10 December 2025;
Published: 12 January 2026.
Edited by:
Ioannis Serafimidis, Biomedical Research Foundation of the Academy of Athens (BRFAA), GreeceReviewed by:
David Hill, Lawson Health Research Institute, CanadaCopyright © 2026 Li, Chen, Wang, Du, Lao, Chen, Yao, Chen, Li, Liu and Xue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiaoguang Xue, eHVlNjk4MDA5QDE2My5jb20=
†These authors have contributed equally to this work